Pharmacogenetics in cancer treatment.

Interindividual variability in the efficacy and toxicity of drug therapy is associated with polymorphisms in genes encoding drug-metabolizing enzymes, transporters, or drug targets. Pharmacogenetics aims to identify individuals predisposed to high risk of toxicity from conventional doses of cancer chemotherapeutic agents. We review the role of genetic polymorphisms in UGT1A1 and TPMT, as well as mutations in DPD, in influencing drug disposition and toxicity. Recent studies show that pharmacogenetic determinants may also influence treatment outcomes. We discuss the clinical significance of polymorphisms in TS, MTHFR, and FCGR3A, as well as the polymorphic DNA repair genes XPD and XRCC1, in influencing response to chemotherapy and survival outcomes. Finally, the potential implications of transporter pharmacogenetics in influencing drug bioavailability are addressed.

[1]  J. Lilleyman,et al.  Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. , 2003, British journal of clinical pharmacology.

[2]  E. Schuetz,et al.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.

[3]  D. Schrenk,et al.  A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. , 2002, Pharmacogenetics.

[4]  M. Krajinovic,et al.  Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia , 2002, The Lancet.

[5]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[6]  S. Groshen,et al.  A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. , 2001, Cancer research.

[7]  L. Kluijtmans,et al.  Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Goldstein,et al.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. , 2001, Pharmacogenetics.

[9]  B. Iacopetta,et al.  A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil , 2001, British Journal of Cancer.

[10]  A. V. van Kuilenburg,et al.  Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  C. Ulrich,et al.  Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. , 2001, Blood.

[12]  S. Groshen,et al.  A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. , 2001, Anticancer research.

[13]  J S Leeder,et al.  Pharmacogenetics and pharmacogenomics. , 2001, Pediatric clinics of North America.

[14]  Martin R. Johnson,et al.  Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. , 2001, Advances in enzyme regulation.

[15]  F. Baas,et al.  Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. McLeod,et al.  MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. , 2001, Pharmacogenetics.

[18]  Yoshiro Saito,et al.  Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[20]  P. Vreken,et al.  Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  S. Ghosh,et al.  Genetic lesions of bilirubin uridine‐diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler‐Najjar and Gilbert syndromes: Correlation of genotype to phenotype , 2000, Human mutation.

[22]  R. Weinshilboum,et al.  Thiopurine methyltransferase polymorphic tandem repeat: Genotype‐phenotype correlation analysis , 2000, Clinical pharmacology and therapeutics.

[23]  H. McLeod,et al.  Known variant DPYD alleles do not explain DPD deficiency in cancer patients. , 2000, Pharmacogenetics.

[24]  M. Dolan,et al.  Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. , 2000, Cancer research.

[25]  D. Crivellari,et al.  MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF) , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  M. West,et al.  XRCC1 keeps DNA from getting stranded. , 2000, Mutation research.

[27]  L. Grochow,et al.  Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[29]  R. Nishimura,et al.  Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. , 1999, Anticancer research.

[30]  D. Nebert,et al.  Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? , 1999, Clinical genetics.

[31]  K. Kawakami,et al.  Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. , 1999, Anticancer research.

[32]  H. McLeod,et al.  Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. , 1999, Genomics.

[33]  M. Relling,et al.  Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. , 1999, Blood.

[34]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[35]  G. Peters,et al.  Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  K. E. Hunt,et al.  Polymorphisms at the Werner locus: I. Newly identified polymorphisms, ethnic variability of 1367Cys/Arg, and its stability in a population of Finnish centenarians. , 1999, American journal of medical genetics.

[37]  G Milano,et al.  © 1999 Cancer Research Campaign Article no. bjoc.1998.0098 Dihydropyrimidine dehydrogenase deficiency and , 2022 .

[38]  E. Reed.  Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. , 1998, Cancer treatment reviews.

[39]  H. McLeod,et al.  Characterization of the human dihydropyrimidine dehydrogenase gene. , 1998, Genomics.

[40]  E. Beutler,et al.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Clegg,et al.  Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. , 1998, American journal of human genetics.

[42]  J. Ledbetter,et al.  Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. , 1998, Blood.

[43]  F. Goldwasser,et al.  Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  S. Groshen,et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  D. Roos,et al.  FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype , 1997 .

[46]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[47]  W. Evans,et al.  Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  B. Burchell,et al.  UGT1*1 genotyping in a Canadian Inuit population. , 1997, Pharmacogenetics.

[49]  H. McLeod,et al.  Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. , 1996, The Journal of clinical investigation.

[50]  B. Burchell,et al.  Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.

[51]  Y. Adachi,et al.  The genetic basis of Gilbert's syndrome , 1996, The Lancet.

[52]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[53]  G. Milano,et al.  Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). , 1994, Anticancer research.

[54]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[55]  P. Bosma,et al.  Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. , 1994, The Journal of biological chemistry.

[56]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[57]  J. Gummert,et al.  Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient , 1993, The Lancet.

[58]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[59]  R. Diasio,et al.  Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome , 1991, Cancer.

[60]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[61]  R. Weinshilboum,et al.  Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia , 1990, The Lancet.

[62]  R. Diasio,et al.  Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. , 1987, Cancer research.

[63]  M. Tuchman,et al.  Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. , 1985, The New England journal of medicine.

[64]  P. Novikoff,et al.  Distribution of UDPglucuronosyltransferase in rat tissue. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[65]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[66]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.

[67]  W. Evans,et al.  Pharmacogenomics: unlocking the human genome for better drug therapy. , 2001, Annual review of pharmacology and toxicology.

[68]  S. Groshen,et al.  Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy , 2001, The Pharmacogenomics Journal.

[69]  M. Poot,et al.  Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase , 1999, Human Genetics.

[70]  M. Yin,et al.  Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  R. Weinshilboum,et al.  Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. , 1996, DNA and cell biology.

[72]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[73]  C. Wasternack,et al.  Degradation of pyrimidines and pyrimidine analogs--pathways and mutual influences. , 1980, Pharmacology & therapeutics.